文献速递临床生化临床血液与体液

血红蛋白C、D、E和S特征对15种HbA1c检测方法干扰的评估

Evaluation of interference from hemoglobin C, D, E and S traits on measurements of hemoglobin A1c by fifteen methods.
PubMed 文献 · Clin Chim Acta · 2021-08-02

该研究评估了血红蛋白C、D Punjab、E或S特征对15种当前HbA1c检测方法的干扰。以硼酸亲和HPLC为比较方法,发现所有方法对一种或多种变异体显示统计学显著影响,其中Tosoh G11变异模式(HbAD)、Roche b 101(HbAC和HbAE)和Siemens DCA Vantage(HbAE和HbAS)观察到临床显著影响,其他方法无临床显著差异。

要点

  • 所有15种方法对一种或多种血红蛋白变异体显示统计学显著影响。
  • Tosoh G11变异模式对HbAD、Roche b 101对HbAC和HbAE、Siemens DCA Vantage对HbAE和HbAS有临床显著干扰。
  • 其余方法未显示临床显著差异,但实验室需知晓潜在干扰。

核心结论

  • 少数方法对一种或多种血红蛋白变异体显示干扰,实验室需注意HbA1c检测的潜在干扰。

研究设计与样本

  • 研究分析了HbAA、HbAC、HbAD Punjab、HbAE和HbAS样本,在2种酶法、4种离子交换HPLC和9种免疫分析方法上检测,以Trinity Premier Hb9210硼酸亲和HPLC为比较方法。
  • 采用最小二乘线性回归线重合性总体检验判断HbA1c结果是否与HbAA样本有统计学显著差异。

主要发现

  • 所有方法对一种或多种变异体显示统计学显著影响。
  • Tosoh G11变异模式对HbAD、Roche b 101对HbAC和HbAE、Siemens DCA Vantage对HbAE和HbAS观察到临床显著影响。
  • 其他方法(Beckman Coulter B93009和B00389 on DxC700AU、Unicel DxC、Ortho Clinical Vitros 5.1、Roche cobas c 513、Siemens Dimension RxL和Vista、Advia和Atellica上的酶法、Tosoh G8 5.24和5.28及GX)未显示临床显著差异。

关键数值与推荐

  • 临床显著干扰定义为在6%或9% HbA1c时,与Premier Hb9210相比,Deming回归显示差异>6%。

临床怎么用

  • 实验室应了解所用HbA1c方法可能受血红蛋白变异体干扰,必要时选择不受干扰的方法或对变异体携带者结果进行解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemoglobin C, D Punjab, E or S trait can interfere with hemoglobin A1c (HbA1c) results. We assessed whether they affect results obtained with 15 current assay methods. METHODS: Hemoglobin AA (HbAA), HbAC, HbAD Punjab, HbAE and HbAS samples were analyzed on 2 enzymatic, 4 ion-exchange HPLC and 9 immunoassay methods. Trinity Premier Hb9210 boronate affinity HPLC was the comparative method. An overall test of coincidence of least-squared linear regression lines was performed to determine if HbA1c results were statistically significantly different from those of HbAA samples. Clinically significant interference was defined as >6% difference from HbAA at 6 or 9% HbA1c compared to Premier Hb9210 using Deming regression. RESULTS: All methods showed statistically significant effects for one or more variants. Clinically significant effects were observed for the Tosoh G11 variant mode (HbAD), Roche b 101 (HbAC and HbAE) and Siemens DCA Vantage (HbAE and HbAS). All other methods (Beckman Coulter B93009 and B00389 on DxC700AU, and Unicel DxC, Ortho Clinical Vitros 5.1, Roche cobas c 513, Siemens Dimension RxL and Vista, and Enzymatic on Advia and Atellica, Tosoh G8 5.24 and 5.28, and GX) showed no clinically significant differences. CONCLUSIONS: A few methods showed interference from one or more variants. Laboratories need to be aware of potential HbA1c assay interferences.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Rohlfing C, Hanson S, Estey MP, et al. Evaluation of interference from hemoglobin C, D, E and S traits on measurements of hemoglobin A1c by fifteen methods. Clin Chim Acta. 2021. PMID: 34352282. doi:10.1016/j.cca.2021.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。